Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis.

The European respiratory journal - 1 Apr 2023

Cavinato Luca, Luly Francesco R, Pastore Valentina, Chiappetta Daniele, Sangiorgi Gloria, Ferrara Eva, Baiocchi Pia, Mandarello Giuseppe, Cimino Giuseppe, Del Porto Paola, Ascenzioni Fiorentina

Abstract excerpt

BACKGROUND: Cystic fibrosis (CF), which is caused by mutations in the CF transmembrane conductance regulator (CFTR), is characterised by chronic bacterial lung infection and inflammation. In CF, monocytes and monocyte-derived macrophages have been shown to display defective phagocytosis and antimicrobial activity against relevant lung pathogens, including Pseudomonas aeruginosa. Thus, we addressed the effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Infective Agents
Share to Cystic Fibrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Monocytes

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 36455959
DOI: 10.1183/13993003.00725-2022
PMCID: PMC10066567

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis.PMID 36455959Read ↗

Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor.Semantic proximity Read ↗

Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis.Semantic proximity Read ↗

CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic FibrosisSemantic proximity Read ↗

The Role of Triple CFTR Modulator Therapy in Reducing Systemic Inflammation in Cystic FibrosisSemantic proximity Read ↗

The effect of highly effective modulator therapy on systemic inflammation in cystic fibrosisSemantic proximity Read ↗

Comparative effects of CFTR modulators on phagocytic, metabolic and inflammatory profiles of CF and nonCF macrophages.Semantic proximity Read ↗

Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa.Semantic proximity Read ↗

Azithromycin Augments Bacterial Uptake and Anti-inflammatory Macrophage Polarization in Cystic FibrosisSemantic proximity Read ↗

Impact of CFTR Modulators on the Impaired Function of Phagocytes in Cystic Fibrosis Lung Disease.Semantic proximity Read ↗

Optimal complement-mediated phagocytosis of Pseudomonas aeruginosa by monocytes is cystic fibrosis transmembrane conductance regulator-dependent.Semantic proximity Read ↗

Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis.Semantic proximity Read ↗

Polymicrobial extracellular vesicles reduce the innate immune response of human cystic fibrosis bronchial epithelial cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.